Login to Your Account



A Regulatory Drama

Phenomix: How Everything Right Can Go So Wrong

By Arlene Weintraub


Monday, November 15, 2010
In October 2008, Phenomix Corp. seemed to be on top of the biotech world. After raising $165 million in venture capital to develop its Type II diabetes compound, dutogliptin, the San Diego start-up scored a development deal with Forest Laboratories Inc. potentially worth $340 million.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription